Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 2/2011

01-04-2011

Optimal Therapy in Hypertensive Subjects with Diabetes Mellitus

Authors: Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Paolo Verdecchia

Published in: Current Atherosclerosis Reports | Issue 2/2011

Login to get access

Abstract

Diabetes and its micro- and macrovascular complications represent a worldwide epidemic that will place an enormous financial burden on poorer countries in the years to come. In patients with diabetes and hypertension, the main determinant of the cardiovascular and renal benefits of antihypertensive drugs is the blood pressure (BP) level achieved under treatment. Quite recently, the paradigm of a BP target < 130/80 mm Hg in these patients has been questioned by a number of trials, including data from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) blood pressure–lowering arm and from the diabetic cohort of International Verapamil SR-Trandolapril Study (INVEST). At the same time, even if the key role of BP control is unquestionable, a growing number of published trials suggest that different antihypertensive combinations may offer specific cardio-, vasculo-, and renoprotective advantages that go beyond BP reduction per se. The present review focuses on the most recent and important literature that explored the “optimal” antihypertensive therapy in patients with type 2 diabetes and concomitant hypertension, and it discusses in detail the various areas of uncertainty, including the specific renoprotective effects of renin-angiotensin system blocking agents and the long-term effects of angiotensin-converting enzyme/angiotensin receptor blocker combinations on the progression of diabetic nephropathy.
Literature
1.
2.
Sowers JR: Treatment of hypertension in patients with diabetes. Arch Intern Med 2004, 164(17):1850–1857.PubMedCrossRef
3.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S et al: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25(6):1105–1187.PubMedCrossRef
4.
MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990, 335(8692):765–774.PubMedCrossRef
5.
Reboldi G, Gentile G, Angeli F, Verdecchia P: Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vascular Health & Risk Management 2009, 5(1):411–427.CrossRef
6.
Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Jr. et al: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545–2559.PubMedCrossRef
7.
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D et al: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560–2572.PubMedCrossRef
8.
DCCT SG: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329(14):977–986.
9.
EDIC SG: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000, 342(6):381–389.CrossRef
10.
UKPDS SG: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):837–853.CrossRef
11.
UKPDS SG: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):854–865.CrossRef
12.
Rossing P: Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 2006, 6(6):479–483.PubMedCrossRef
13.
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr. et al: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42(6):1206–1252.PubMedCrossRef
14.
Greenberg A: Diuretic complications. American Journal of the Medical Sciences 2000, 319(1):10–24.PubMedCrossRef
15.
Zillich AJ, Garg J, Basu S, Bakris GL, Carter BL: Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006, 48(2):219–224.PubMedCrossRef
16.
McFarlane SI, Kumar A, Sowers JR: Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol 2003, 91(12A):30 H–37 H.PubMedCrossRef
17.
Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, Horiuchi M: ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002, 40(3):329–334.PubMedCrossRef
18.
Schupp M, Janke J, Clasen R, Unger T, Kintscher U: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004, 109(17):2054–2057.PubMedCrossRef
19.
Ozaki N, Nomura Y, Sobajima H, Kondo K, Oiso Y: Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. Eur J Intern Med 2010, 21(3):236–239.PubMedCrossRef
20.
Fogari R, Derosa G, Zoppi A, Lazzari P, Corradi L, Preti P, Mugellini A: Effect of delapril/manidipine vs olmesartan/hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern Med 2008, 47(5):361–366.PubMedCrossRef
21.
Draznin B, Sussman KE, Eckel RH, Kao M, Yost T, Sherman NA: Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia. J Clin Invest 1988, 82(6):1848–1852.PubMedCrossRef
22.
Bell DS: Beta-adrenergic blocking agents in patients with diabetes—friend and foe. Endocr Pract 1999, 5(1):51–53.PubMed
23.
Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, De Angelis L, D’Onofrio F: Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997, 126(12):955–959.PubMed
24.
Hunter SJ, Wiggam MI, Ennis CN, Whitehead HM, Sheridan B, Atkinson AB, Bell PM: Comparison of effects of captopril used either alone or in combination with a thiazide diuretic on insulin action in hypertensive Type 2 diabetic patients: a double-blind crossover study. Diabet Med 1999, 16(6):482–487.PubMedCrossRef
25.
McLaughlin DM, Atkinson AB, Ennis CN, Browne J, Hunter SJ, Sheridan B, Bell PM: Comparison of effects of combined ACE inhibitor and low-dose thiazide diuretic with ACE inhibitor alone on insulin action in patients with hypertension and Type 2 diabetes: a double-blind crossover study. Diabet Med 2008, 25(5):631–634.PubMedCrossRef
26.
Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M et al: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007, 370(9590):829–840.PubMedCrossRef
27.
Kinouchi K, Ichihara A, Sakoda M, Kurauchi-Mito A, Itoh H: Safety and benefits of a tablet combining losartan and hydrochlorothiazide in Japanese diabetic patients with hypertension. Hypertens Res 2009, 32(12):1143–1147.PubMedCrossRef
28.
Reboldi G, Gentile G, Angeli F, Verdecchia P: Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Rev Cardiovasc Ther 2009, 7(11):1349–1361.PubMedCrossRef
29.
Fernandez R, Puig JG, Rodriguez-Perez JC, Garrido J, Redon J: Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Hum Hypertens 2001, 15(12):849–856.PubMedCrossRef
30.
Holzgreve H, Nakov R, Beck K, Janka HU: Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 2003, 16(5 Pt 1):381–386.PubMedCrossRef
31.
Fogari R, Derosa G, Zoppi A, Rinaldi A, Preti P, Lazzari P, Mugellini A: Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Hypertens Res 2008, 31(1):43–50.PubMedCrossRef
32.
• Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Jr., Oakes R, Lukas MA et al: Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004, 292(18):2227–2236. In hypertensive diabetics of the large GEMINI trial, the mean HBA1c increased with traditional beta-blocker metoprolol, whereas newer beta-blocker carvedilol caused no adverse metabolic effects.
33.
Bell DSH, Bakris GL, McGill JB: Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes, Obesity & Metabolism 2009, 11(3):234–238.CrossRef
34.
Kveiborg B, Hermann TS, Major-Pedersen A, Christiansen B, Rask-Madsen C, Raunso J, Kober L, Torp-Pedersen C, Dominguez H: Metoprolol compared to carvedilol deteriorates insulin-stimulated endothelial function in patients with type 2 diabetes—a randomized study. Cardiovasc 2010, 9:21.
35.
Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, Woodward M, MacMahon S: Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005, 165(12):1410–1419.PubMedCrossRef
36.
Vijan S, Hayward RA: Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003, 138(7):593–602.PubMed
37.
UKPDS SG: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998, 317(7160):703–713.
38.
Estacio RO, Jeffers BW, Gifford N, Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000, 23 Suppl 2:B54–64.PubMed
39.
Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351(9118):1755–1762.PubMedCrossRef
40.
ADA: Standards of medical care in diabetes—2010. Diabetes Care 2010, 33 Suppl 1:S11–61.
41.
Zanchetti A, Grassi G, Mancia G: When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009, 27(5):923–934.PubMedCrossRef
42.
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clement D, Coca A, Dominiczak A et al: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009, 27(11):2121–2158.PubMedCrossRef
43.
•• Cushman WC, Evans GW, Byington RP, Goff DC, Jr., Grimm RH, Jr., Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL et al: Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010, 362(17):1575–1585. In the ACCORD trial, which compared a tighter (<120 mmHg) with a less-tight (<140 mmHg) systolic BP goal in patients with diabetes, the incidence of the primary endpoint, a composite of fatal and non-fatal cardiovascular events, did not differ between the two groups, nor did the incidence of myocardial infarction. PubMedCrossRef
44.
•• Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ: Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. JAMA 2010, 304(1):61–68. In the diabetic cohort of the INVEST trial, 6400 patients with concomitant hypertension and coronary artery disease were assigned to three groups according to their average systolic BP while taking study medication: 1) tight control (BP < 130 mm Hg); 2) usual control (BP 130 mm Hg to < 140 mm Hg); or 3) uncontrolled (BP ≥ 140 mm Hg). This study confirms the ACCORD findings of no additional benefits for a very tight BP control in patients with diabetes and hypertension. PubMedCrossRef
45.
Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R, Pepine CJ, for the II: Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study. Hypertension 2004, 44(5):637–642.PubMedCrossRef
46.
Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, Howard WJ, Lee ET, Mete M, Poolaw B et al: Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA 2008, 299(14):1678–1689.PubMedCrossRef
47.
Lameire N: Diabetes and diabetic nephropathy—a worldwide problem. Acta Diabetol 2004, 41 Suppl 1:S3–5.PubMedCrossRef
48.
Zarif L, Covic A, Iyengar S, Sehgal AR, Sedor JR, Schelling JR: Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrology Dialysis Transplantation 2000, 15(11):1801–1807.CrossRef
49.
Martin R, Gorostidi M, Diez Ojea B: [Nephrosclerosis. The Cinderella of chronic kidney disease]. Nefrologia 2010, 30(3):275–279.PubMed
50.
Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006, 69(11):2057–2063.PubMedCrossRef
51.
Wu AY, Kong NC, de Leon FA, Pan CY, Tai TY, Yeung VT, Yoo SJ, Rouillon A, Weir MR: An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2005, 48(1):17–26.PubMedCrossRef
52.
Parving HH: Blockade of the renin-angiotensin-aldosterone system and renal protection in diabetes mellitus. J Renin Angiotensin Aldosterone Syst 2000, 1(1):30–31.PubMedCrossRef
53.
Strippoli GFM, Craig M, Schena FP, Craig JC: Antihypertensive Agents for Primary Prevention of Diabetic Nephropathy. Journal of the American Society of Nephrology 2005, 16(10):3081–3091.PubMedCrossRef
54.
Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345(12):870–878.PubMedCrossRef
55.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993, 329(20):1456–1462.
56.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345(12):861–869.PubMedCrossRef
57.
Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M: Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992, 304(6823):339–343.PubMedCrossRef
58.
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345(12):851–860.PubMedCrossRef
59.
Siragy HM, de Gasparo M, El-Kersh M, Carey RM: Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 2001, 38(2):183–186.PubMed
60.
Weir MR: The renoprotective effects of RAS inhibition: focus on prevention and treatment of chronic kidney disease. Postgrad Med 2009, 121(1):96–103.PubMedCrossRef
61.
Suissa S, Hutchinson T, Brophy JM, Kezouh A: ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006, 69(5):913–919.PubMedCrossRef
62.
Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ: Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005, 366(9502):2026–2033.PubMedCrossRef
63.
Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Jr., Whelton PK, Barzilay J, Batuman V, Eckfeldt JH, Farber M et al: Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005, 165(8):936–946.PubMedCrossRef
64.
Rossing P, Parving H-H, de Zeeuw D: Renoprotection by blocking the RAAS in diabetic nephropathy—fact or fiction? Nephrology Dialysis Transplantation 2006, 21(9):2354–2357.CrossRef
65.
Remuzzi G, Perico N, Macia M, Ruggenenti P: The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005(99):S57–65.PubMedCrossRef
66.
Raij L: The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. Am J Hypertens 2005, 18(4 Pt 2):95 S–99 S.PubMedCrossRef
67.
•• Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S et al: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. The Lancet 2008, 372(9638):547–553. In the ONTARGET trial, ACE/ARB combination allowed a greater reduction in urinary albumin/creatinine ratio, but such reduction did not translate into an overall lower rate of renal events. This study raised concerns about dual-agent blockade of the renin–angiotensin–aldosterone system, particularly about the potential increase in the incidence of hyperkalemia and decrease in the glomerular filtration rate. CrossRef
68.
Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J: Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007, 24(5):486–493.PubMedCrossRef
69.
Krairittichai U, Chaisuvannarat V: Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. Journal of the Medical Association of Thailand 2009, 92(5):611–617.PubMed
70.
Tan F, Mukherjee JJ, Lee KO, Lim P, Liew CF: Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. Singapore Medical Journal 2010, 51(2):151–156.PubMed
71.
Halimi JM, Mimran A: ONTARGET: does dual blockade of the renin-angiotensin system provide more effective cardiovascular and renal protection in patients at high cardiovascular risk? Curr Hypertens Rep 2009, 11(2):85–87.PubMedCrossRef
72.
Berns JS: Is angiotensin-converting enzyme inhibitor and angiotensin receptor blocker combination therapy better than monotherapy and safe in patients with CKD? Am J Kidney Dis 2009, 53(2):192–196.PubMedCrossRef
73.
•• Fried LF, Duckworth W, Zhang JH, O'Connor T, Brophy M, Emanuele N, Huang GD, McCullough PA, Palevsky PM, Seliger S et al: Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009, 4(2):361–368. The VA NEPHRON-D, a multicenter, prospective, randomized, parallel group trial, will investigate the long-term effect of an ACE/ARB combination on the progression of diabetic nephropathy in 1850 patients with type 2 diabetes, overt nephropathy, and estimated glomerular filtration rate between 30 and 89.9 mL/min/1.73 m 2 . VA NEPHRON-D will help answer the important clinical questions raised in ONTARGET. PubMedCrossRef
74.
de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, Neal B, Poulter N, Harrap S, Mogensen C-E et al: Lowering blood pressure reduces renal events in type 2 diabetes. Journal of the American Society of Nephrology 2009, 20(4):883–892.PubMedCrossRef
75.
Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359(23):2417–2428.PubMedCrossRef
76.
•• Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlof B, Kelly RY, Hua TA et al: Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010, 56(1):77–85. In the diabetic cohort of ACCOMPISH, the authors demonstrated a striking superiority of the benazepril/amlodipine combination, as compared with benazepril/hydrochlorothiazide, in reducing the primary outcome, a composite of cardiovascular death, myocardial infarction, stroke, hospitalized angina, resuscitated arrest, and coronary revascularization, during the 30 months of follow-up. PubMedCrossRef
77.
Verdecchia P, Gentile G, Angeli F, Mazzotta G, Mancia G, Reboldi G: Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens 2010, 28(7):1356–1365.PubMedCrossRef
78.
Bakris GL, Sarafidis PA, Weir MR, Dahlof B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V et al: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010, 375(9721):1173–1181.PubMedCrossRef
79.
Bassler D, Montori VM, Briel M, Glasziou P, Guyatt G: Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol 2008, 61(3):241–246.PubMedCrossRef
80.
Heerspink HL, de Zeeuw D: Composite renal endpoints: was ACCOMPLISH accomplished? Lancet 2010, 375(9721):1140–1142.PubMedCrossRef
81.
•• Bakris GL, Toto RD, McCullough PA, Rocha R, Purkayastha D, Davis P: Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008, 73(11):1303–1309. In patients with diabetes, hypertension, and microalbuminuria in the GUARD trial, rates of progression to overt diabetic nephropathy were similar between the benazepril/amlodipine and the benazepril/hydrochlorothiazide group, but the mean decrease in the estimated glomerular filtration rate over the 52-week period was less in the benazepril/amlodipine group than in the benazepril/hydrochlorothiazide group. PubMedCrossRef
82.
Janssen PG, Gorter KJ, Stolk RP, Rutten GE: Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract 2009, 59(558):43–48.PubMedCrossRef
83.
Edelman D, Fredrickson SK, Melnyk SD, Coffman CJ, Jeffreys AS, Datta S, Jackson GL, Harris AC, Hamilton NS, Stewart H et al: Medical clinics versus usual care for patients with both diabetes and hypertension: a randomized trial. Annals of Internal Medicine 2010, 152(11):689–696.PubMed
84.
Powers BJ, Olsen MK, Oddone EZ, Bosworth HB: The effect of a hypertension self-management intervention on diabetes and cholesterol control. Am J Med 2009, 122(7):639–646.PubMedCrossRef
85.
Williams AF, Manias E, Walker RG: The devil is in the detail—a multifactorial intervention to reduce blood pressure in co-existing diabetes and chronic kidney disease: a single blind, randomized controlled trial. BMC Fam Pract 2010, 11:3.PubMedCrossRef
Metadata
Title
Optimal Therapy in Hypertensive Subjects with Diabetes Mellitus
Authors
Gianpaolo Reboldi
Giorgio Gentile
Fabio Angeli
Paolo Verdecchia
Publication date
01-04-2011
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 2/2011
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-011-0160-9

Other articles of this Issue 2/2011

Current Atherosclerosis Reports 2/2011 Go to the issue

ReviewPaper

Developmental Mechanisms Involved in the Primary Prevention of Atherosclerosis and Cardiovascular Disease

Clinical Trial Report

Omega-3 Fatty Acids and Cardiovascular Events after Myocardial Infarction: The Alpha Omega Trial

ReviewPaper

Evolving Concepts of the Role of High-Density Lipoprotein in Protection from Atherosclerosis

ReviewPaper

Vasculotoxic Effects of Insulin and Its Role in Atherosclerosis: What is the Evidence?

Clinical Trial Report

Effects of Combination Lipid Therapy in Diabetes Mellitus

ReviewPaper

Obstructive Sleep Apnea and the Risk for Cardiovascular Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits